CUTISS is pleased to announce that a tissue graft patent has been granted by the European Patent Office for the personalized bioengineered human skin tissue therapy developed by CUTISS.
The patent (3174563) has been granted pursuant to Article 97(1) EPC to University of Zurich (UZH) where the founders of CUTISS worked at the time of the patent filing (2014), and is exclusively licensed to CUTISS.
This patent strengthens the company’s intellectual property position in human tissue graft technologies.
CUTISS’s first skin tissue therapy product denovoSkin is currently in Phase IIb clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.
The mention of the grant has been published in the European Patent Bulletin 22/24.